Capital World Investors Neurocrine Biosciences Inc Transaction History

Capital World Investors

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $20.5 Million - $37.3 Million	-300,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $35.4 Million - $45.1 Million	-358,000 Reduced 54.41%	300,000 $36.9 Million
Q2 2018 Aug 14, 2018	SELL	$75.3 - $105.99 $2.26 Million - $3.18 Million	-30,000 Reduced 4.36%	658,000 $64.6 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $33 Million - $42.2 Million	688,000	688,000 $42.2 Million

656

96.6M

282K

281K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $10.7B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

Stay updated on Capital World Investors with notifications on news.